Home > Journals > Biology and research > summary
 
      Advanced search    Shopping cart    French version 
 
Latest books
Catalogue/Search
Collections
All journals
Medicine
Biology and research
Journal de Pharmacie Clinique
- Current issue
- Archives
- Subscribe
- Order an issue
- More information
Public health
Agronomy and biotech.
My account
Forgotten password?
Online account   activation
Subscribe
Licences IP
- Instructions for use
- Estimate request form
- Licence agreement
Order an issue
Pay-per-view articles
Newsletters
How can I publish?
Journals
Books
Help for advertisers
Foreign rights
Book sales agents



 

Texte intégral de l'article
 
Printable version

Acute leukemia and anti-tuberculosis treatment: therapeutic problems


Journal de Pharmacie Clinique. Volume 21, Number 2, 137-40, Juin 2002, Cas cliniques

Résumé   Article gratuit  

Author(s) : F. LAPORTE, V. FAVRE, K. SAVELLI, F. HUGUET, J.-M. CANONGE, M. VIE, J. PRIS

Summary : Mrs L., 59 years-old, is hospitalized for acute myeloblastic leukaemia (AML). At entry, a biopsy of clinically suspected cervical adenopathy does not allow the distinction between sarcoidosis and reactivation tuberculosis. An antituberculosis quadritherapy is added to the anti leukemic chemotherapy. It is therefore necessary to control hepatic function and biochemistry. Potential drug interactions imply a precision in the rythm of administration for some drugs, namely fluconazol and rifampicin. Three months later, negative microbiologic examinations allow to stop antituberculosis treatment. Thirty months after the start of treatment, the patient is still in a remission status for her AML.

Keywords : leukemia, adenopathy, interactions, liver toxicity, sarcoidosis.

 

About us - Contact us - Conditions of use - Secure payment
Latest news - Conferences
Copyright © 2007 John Libbey Eurotext - All rights reserved
[ Legal information - Powered by Dolomède ]